Articles by Christine Parseghian, MD
The panel concludes with an in-depth discussion on the evolving role of ctDNA in colorectal cancer management.
The panel highlights the BREAKWATER study and explores practical considerations for therapy before biomarker results.
The panel discusses strategies for IO in CRC, including the ATOMIC trial and adoption of neoadjuvant checkpoint inhibition.
The panel explores the evolving treatment landscape for patients with MSI-high metastatic colorectal cancer.
The panel dives into the role of biomarker testing in CRC, noting how next-gen sequencing and MSI testing are essential.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.
;